MacroGenics, Inc. (MGNX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Scott Koenig M.D., Ph.D. | President, CEO & Director | 1.2M | -- | 1952 |
| Mr. James Karrels | Senior VP, CFO & Corporate Secretary | 693.31k | -- | 1967 |
| Dr. Stephen L. Eck M.D., Ph.D. | Senior VP of Clinical Development & Chief Medical Officer | 766.85k | -- | 1955 |
| Mr. Eric Blasius Risser | Chief Operating Officer | 651.36k | -- | 1973 |
| Dr. Thomas M. Spitznagel Ph.D. | Senior Vice President of Technical Operations | 550.97k | 204.5k | 1967 |
| Dr. Ezio Bonvini M.D. | Senior VP of Research & Chief Scientific Officer | 612.21k | 264.03k | 1954 |
| Mr. Jeffrey Stuart Peters | Senior VP, General Counsel & Corporate Compliance Officer | -- | -- | 1971 |
| Ms. Lynn Cilinski | VP, Controller & Treasurer | -- | -- | 1958 |
MacroGenics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 339
Description
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Corporate Governance
Recent Events
- Apr 08, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Apr 03, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 07, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 24, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Nov 14, 2023CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submissionSee Full Filing